Painchek (ASX:PCK) Cash-to-Debt: No Debt (1) (As of Dec. 2025) — 100% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Painchek Cash-to-Debt?

Painchek ASX:PCK -5.10% Cash-to-Debt is No Debt (1) as of Dec. 2025, which is 100% below its 10-year median of 10,000.00. The stock has 3 warning signs investors should review. Among 663 Healthcare Providers & Services companies, Painchek ranks better than 99.85% on this metric.

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Painchek's cash to debt ratio for the quarter that ended in Dec. 2025 was No Debt (1).

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Painchek could pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Painchek's Cash-to-Debt or its related term are showing as below:

ASX:PCK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11   Med: No Debt   Max: No Debt
Current: No Debt

During the past 13 years, Painchek's highest Cash to Debt Ratio was No Debt. The lowest was 0.11. And the median was No Debt.

ASX:PCK's Cash-to-Debt is ranked better than
99.85% of 663 companies
in the Healthcare Providers & Services industry
Industry Median: 0.77 vs ASX:PCK: No Debt

Painchek  (ASX:PCK) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Painchek Cash-to-Debt Related Terms


Painchek Cash-to-Debt Historical Data

* Premium members only.

The historical data trend for Painchek's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Painchek Cash-to-Debt Chart

Painchek Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt No Debt

Painchek Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt No Debt

ASX:PCK vs VEEV, BTSG, HQY: Cash-to-Debt Comparison

For the Health Information Services subindustry, Painchek's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Painchek Cash-to-Debt vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Painchek's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Painchek's Cash-to-Debt falls into.



Painchek Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Painchek's Cash to Debt Ratio for the fiscal year that ended in Jun. 2025 is calculated as:

Painchek had no debt (1).

Painchek's Cash to Debt Ratio for the quarter that ended in Dec. 2025 is calculated as:

Painchek had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash-to-Debt →
What does a Cash-to-Debt of No Debt <sup>(1)</sup> mean?
Painchek (ASX:PCK) has a Cash-to-Debt of No Debt (1) as of Dec. 2025. This is 100% below median its historical median of 10,000.00. Over the past decade, Painchek's Cash-to-Debt has ranged from 0.11 to 10,000.00. According to the industry distribution chart, Painchek ranks #1 out of 663 companies in the Healthcare Providers & Services industry, placing it in the top 0.2%.
Is Painchek's Cash-to-Debt too high?
Painchek's current Cash-to-Debt of No Debt (1) is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 10,000.00. Based on the distribution chart, Painchek ranks #1 out of 663 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does Painchek's Cash-to-Debt compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Painchek ranks #1 out of 663 companies for Cash-to-Debt. This places Painchek in the top 0% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.77. Historically, Painchek's own Cash-to-Debt has ranged from 0.11 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.77, based on 663 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Painchek's current Cash-to-Debt is No Debt (1), which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Painchek stock overvalued right now?
Based on GuruFocus' analysis, Painchek (ASX:PCK) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.41, compared to a current price of A$0.09 — trading 77.3% below its estimated fair value. The current Cash-to-Debt is No Debt (1), which is 100% below median its 10-year median of 10,000.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Painchek (ASX:PCK), the current Cash-to-Debt is No Debt (1) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Painchek Business Description

Address 35 Lime Street, Suite 401, Sydney, NSW, AUS, 2000
Painchek Ltd is engaged in the development and commercialization of mobile medical device applications that provide pain assessment for individuals who are unable to communicate pain with carers. It operates in one segment, namely the sale of its pain assessment solutions. Its geographic segments include Australia, the United Kingdom, and Other countries, of which it generates the majority of its revenue from Australia.